A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs ABBV-321 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 08 Nov 2017 Planned End Date changed from 3 May 2019 to 10 Mar 2024.
- 08 Nov 2017 Status changed from not yet recruiting to recruiting.
- 08 Aug 2017 New trial record